Skip to main content
SpringerLink
Log in

Optimizing conventional therapy for inflammatory bowel disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Recently, conventional therapies for inflammatory bowel disease (IBD) have not received the same amount of attention as biologic therapies, yet they remain the backbone of therapy for IBD because of their efficacy, safety, and relatively low cost. Advances in efficacy and safety continue because of modifications in drug dosing and monitoring. Higher doses of mesalamine per pill, together with once-daily dosing, may help to optimize drug delivery and patient compliance. Budesonide, an effective agent for both induction and short-term remission maintenance in Crohn’s disease, is devoid of many of the toxicities common to corticosteroids. Assessments of thiopurine methyltransferase and metabolite levels are helping to fine-tune dose optimization for the thiopurines azathioprine and 6-mercaptopurine. The oral calcineurin inhibitors tacrolimus and cyclosporine have been shown to have expanded roles in IBD, and methotrexate may be useful in some patients with refractory ulcerative colitis. Probiotics are showing promise for maintenance of remission in Crohn’s disease, ulcerative colitis, and pouchitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Kozuch PL, Hanauer SB: Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008, 14:354–377.

    Article  PubMed  CAS  Google Scholar 

  2. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004, 99:1371–1385.

    Article  PubMed  Google Scholar 

  3. Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD: Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979–994.

    Article  PubMed  Google Scholar 

  4. Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD: Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006, 12:972–978.

    Article  PubMed  Google Scholar 

  5. Hanauer SB, Sandborn WJ, Dallaire C, et al.: Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007, 21:827–834.

    PubMed  CAS  Google Scholar 

  6. Hanauer SB, Sandborn WJ, Kornbluth A, et al.: Delayedrelease oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005, 100:2478–2485.

    Article  PubMed  CAS  Google Scholar 

  7. Brunner M, Assandri R, Kletter K, et al.: Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003, 17:395–402.

    Article  PubMed  CAS  Google Scholar 

  8. Prantera C, Viscido A, Biancone L, et al.: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005, 11:421–427.

    Article  PubMed  Google Scholar 

  9. Lichtenstein GR, Kamm MA, Boddu P, et al.: Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007, 5:95–102.

    Article  PubMed  CAS  Google Scholar 

  10. Kamm MA, Sandborn WJ, Gassull M, et al.: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132:66–75.

    Article  PubMed  CAS  Google Scholar 

  11. Lichtenstein GR, Kamm MA, Sandborn WJ, et al.: MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008, 27:1094–1102.

    Article  PubMed  CAS  Google Scholar 

  12. Kamm MA, Lichtenstein GR, Sandborn WJ, et al.: Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008, 57:893–902.

    Article  PubMed  CAS  Google Scholar 

  13. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940–987.

    Article  PubMed  CAS  Google Scholar 

  14. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935–939.

    Article  PubMed  Google Scholar 

  15. Dahlberg E, Thalen A, Brattsand R, et al.: Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 1984, 25:70–78.

    PubMed  CAS  Google Scholar 

  16. Brattsand R: Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990, 4:407–414.

    Google Scholar 

  17. Hanauer S, Sandborn WJ, Persson A, Persson T: Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005, 21:363–371.

    Article  PubMed  CAS  Google Scholar 

  18. de Jong DJ, Bac DJ, Tan G, et al.: Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn’s disease in remission. Neth J Med 2007, 65:339–345.

    PubMed  Google Scholar 

  19. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713.

    Article  PubMed  CAS  Google Scholar 

  20. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651–662.

    PubMed  CAS  Google Scholar 

  21. Ganiere-Monteil C, Medard Y, Lejus C, et al.: Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 2004, 60:89–96.

    Article  PubMed  CAS  Google Scholar 

  22. Rossi AM, Bianchi M, Guarnieri C, et al.: Genotypephenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001, 57:51–54.

    Article  PubMed  CAS  Google Scholar 

  23. Morales A, Salguti S, Miao CL, Lewis JD: Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:380–385.

    Article  PubMed  Google Scholar 

  24. Sparrow MP, Hande SA, Friedman S, et al.: Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209–214.

    Article  PubMed  CAS  Google Scholar 

  25. Gonzalez-Lama Y, Gisbert JP, Mate J: The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006, 51:1833–1840.

    Article  PubMed  CAS  Google Scholar 

  26. Hart AL, Plamondon S, Kamm MA: Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007, 13:245–253.

    Article  PubMed  Google Scholar 

  27. Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380–388.

    Article  PubMed  CAS  Google Scholar 

  28. Gonzalez-Lama Y, Abreu L, Vera MI, et al.: Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn’s disease: a pilot study. Inflamm Bowel Dis 2005, 11:8–15.

    Article  PubMed  Google Scholar 

  29. Ogata H, Matsui T, Nakamura M, et al.: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255–1262.

    Article  PubMed  CAS  Google Scholar 

  30. Baumgart DC, Pintoffl JP, Sturm A, et al.: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a longterm follow-up. Am J Gastroenterol 2006, 101:1048–1056.

    Article  PubMed  CAS  Google Scholar 

  31. Ng SC, Arebi N, Kamm MA: Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:129–134.

    Article  PubMed  Google Scholar 

  32. Yamamoto S, Nakase H, Mikami S, et al.: Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008, 28:589–597.

    Article  PubMed  CAS  Google Scholar 

  33. Ziring DA, Wu SS, Mow WS, et al.: Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007, 45:306–311.

    Article  PubMed  CAS  Google Scholar 

  34. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.

    Article  PubMed  CAS  Google Scholar 

  35. Weber A, Fein F, Koch S, et al.: Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006, 12:1131–1135.

    Article  PubMed  Google Scholar 

  36. Cacheux W, Seksik P, Lemann M, et al.: Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008, 103:637–642.

    Article  PubMed  CAS  Google Scholar 

  37. Aceituno M, Garcia-Planella E, Heredia C, et al.: Steroidrefractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008, 14:347–352.

    Article  PubMed  Google Scholar 

  38. Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  39. Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995, 332:292–297.

    Article  PubMed  CAS  Google Scholar 

  40. Cummings JR, Herrlinger KR, Travis SP, et al.: Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21:385–389.

    Article  PubMed  CAS  Google Scholar 

  41. Ewaschuk JB, Dieleman LA: Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006, 12:5941–5950.

    PubMed  CAS  Google Scholar 

  42. Miele E, Baldassano R, Pascarella F, et al.: Effect of a probiotic preparation (Vsl #3) on induction and maintenance of remission in children with ulcerative colitis [abstract 1013]. Gastroenterology 2008, 134:A–153.

    Article  Google Scholar 

  43. Makharia GK, Sood A, Midha V, et al.: A randomized, doubleblind, placebo-controlled trial of a probiotic preparation, Vsl#3, for the treatment of mild to moderate active ulcerative colitis [abstract 701]. Gastroenterology 2008, 134:A–99.

    Article  Google Scholar 

  44. Madsen K, Backer J, Leddin D, et al.: A randomized controlled trial of Vsl#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease [abstract M1207]. Gastroenterology 2008, 134:A–361.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Gastroenterology, The University of Chicago Hospitals and Clinics, 5841 South Maryland Avenue, MC 4076, Chicago, IL, 60637-1463, USA

    Russell Cohen

Authors
  1. Marc Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell Cohen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, M., Cohen, R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 10, 585–590 (2008). https://doi.org/10.1007/s11894-008-0106-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-008-0106-8

Keywords

Search

Navigation